Accelerated LBBP for Patients With RHF and Severe TR
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: permanent pacemaker implantation.
- Who it may be relevant to
- Registry conditions: Right Heart Failure. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Accelerated Left Branch Bundle Pacing in the Treatment of Right Heart Failure With Severe Tricuspid Regurgitation: A Prospective, Multicenter, Single-Arm Target Value Clinical Trial
Overview
This study is a prospective, single-arm, target value clinical trial. We plan to prospectively enroll and follow 24 patients across three centers nationwide who have a low baseline heart rate (HR ≤ 60 bpm), meet the indication for permanent pacemaker implantation, and have right-sided heart failure with severe or greater tricuspid regurgitation. All patients will undergo pacemaker implantation using left bundle branch pacing (LBBP), and the pacing rate will be uniformly increased to 90 bpm (reduced to 80-85 bpm in case of intolerance). Patients will be followed for 6 months to evaluate the effects of heart-rate increase on hemodynamics, heart failure symptoms, and physical function in patients with right-sided heart failure.
Detailed description
After eligibility screening and written informed consent are obtained, all participants will undergo baseline assessments including vital signs, biochemical tests, New York Heart Association (NYHA) functional class, diuretic index, edema grade, echocardiographic parameters, 6-minute walk distance (6MWD), and the Kansas City Cardiomyopathy Questionnaire (KCCQ). All patients will then receive pacemaker implantation with the lead positioned for left bundle branch pacing to achieve conduction system pacing. The pacing rate will initially be set at 60 bpm, followed by right heart catheterization. Hemodynamic parameters will be recorded during both diastole and systole, including pressures in the superior vena cava, inferior vena cava, right atrium, right ventricle, and pulmonary artery. Mean pressure values will then be calculated, and mean pulmonary capillary wedge pressure and pulmonary vascular resistance will be measured. Cardiac output (CO) will be assessed invasively using a cardiac output monitoring system integrated with the right heart catheterization setup, based on the Fick principle. The pacing rate will then be increased to 90 bpm; after 5 minutes of stabilization, right heart catheterization will be repeated.
On the day after pacemaker implantation, transthoracic echocardiography (TTE) will be performed, and relevant parameters will be measured at pacing rates of 60 and 90 bpm. Before discharge, the pacing rate will be set to 90 bpm. Diuretics will be prescribed as clinically indicated, and escalation of diuretic dosage will not be permitted during the follow-up period.
Follow-up visits will be scheduled at 1 month, 3 months, and 6 months after discharge. Assessments at each visit will include vital signs, biochemical tests, NYHA functional class, diuretic index, edema grade, KCCQ score, 6MWD, and echocardiographic parameters.
Interventions
- Procedure permanent pacemaker implantation
Implant a pacemaker using left bundle branch pacing (LBBP) and set the pacing rate to 90 bpm.
Primary outcome measures
- An increase of ≥10 points in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score at the 6-month follow-up compared with baseline. [Time frame: From enrollment to the 6-month follow-up]
Secondary outcome measures (8)
- New York Heart Association (NYHA) functional class at the 1-, 3-, and 6-month follow-up visits. [Time frame: From enrollment to the 6-month follow-up]
- The Kansas City Cardiomyopathy Questionnaire (KCCQ) score at the 1-, 3-, and 6-month follow-up visits [Time frame: From enrollment to the 6-month follow-up]
- The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at the 1-, 3-, and 6-month follow-up visits. [Time frame: From enrollment to the 6-month follow-up]
- 6-minute walk distance (6MWD) at the 1-, 3-, and 6-month follow-up visits [Time frame: From enrollment to the 6-month follow-up]
- N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration at the 1-, 3-, and 6-month follow-up visits. [Time frame: From enrollment to the 6-month follow-up]
- Diuretic index at the 1-, 3-, and 6-month follow-up visits [Time frame: From enrollment to the 6-month follow-up]
- Edema index at the 1-, 3-, and 6-month follow-up visits [Time frame: From enrollment to the 6-month follow-up]
- Tricuspid regurgitation severity measured by transthoracic echocardiography at the 1-, 3-, and 6-month follow-up visits. [Time frame: From enrollment to the 6-month follow-up]
Eligibility criteria
Inclusion criteria
- Mean resting heart rate ≤ 65 beats/min (based on a resting electrocardiogram).
- Clinically confirmed right-sided heart failure, requiring ≥2 diuretic units to fully control edema, or having persistent grade ≥1 edema despite diuretic therapy.
Diuretic unit definition: expressed as the number of daily doses at the standard oral dose. For example, the standard units for furosemide, torasemide, and spironolactone are 20 mg/day, 10 mg/day, and 20 mg/day, respectively. If a patient takes furosemide 20 mg twice daily and spironolactone 20 mg once daily, the total diuretic units equal 3.
- Echocardiography shows severe or greater tricuspid regurgitation.
- With/without an indication for permanent pacemaker implantation.
- Is able to understand the purpose of the trial, voluntarily participates and signs written informed consent, and is willing to complete follow-up visits as required by the protocol.
Exclusion criteria
- Mean pulmonary artery pressure (mPAP) > 35 mmHg measured by right heart catheterization at a pacing rate of 60 bpm.
- Left ventricular ejection fraction (LVEF) < 50% or left ventricular end-diastolic diameter (LVEDD) > 56 mm as measured by echocardiography.
- Prior implantation of a cardiac pacemaker.
- Moderate or greater left-sided valvular regurgitation or stenosis.
- Current use of heart rate-lowering medications, such as beta-blockers, digoxin, ivabradine, etc.
- Untreated hypothyroidism.
- Participation in another drug or medical device clinical trial that has not yet been completed.
- Deemed unsuitable for participation in this clinical trial by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 3 centers
- The First Affiliated Hospital of Nanchang University — Nanchang
- Shanghai Zhongshan Hospital — Shanghai
- Shanghai Geriatric Medical Center — Shanghai
Identifiers
NCT: NCT07470047 · B2026-103